MSF Field Research >
1 Published Research and Commentary >
Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.
this identifier to cite or link
to this item:
|Title: ||Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies.|
|Affiliation: ||Division of International and Environmental Health, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland. firstname.lastname@example.org|
|Citation: ||Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studies. 2012, 61 (1):41-8 J. Acquir. Immune Defic. Syndr.|
|Journal: ||Journal of acquired immune deficiency syndromes (1999)|
|Issue Date: ||1-Sep-2012 |
|PubMed ID: ||22743595|
|Additional Links: ||http://www.ncbi.nlm.nih.gov/pubmed/22743595|
|Abstract: ||Tenofovir (TDF) is increasingly used in second-line antiretroviral treatment (ART) in sub-Saharan Africa. We compared outcomes of second-line ART containing and not containing TDF in cohort studies from Zambia and the Republic of South Africa (RSA).|
|Description: ||Article approval pending|
Africa South of the Sahara
Antiretroviral Therapy, Highly Active
CD4 Lymphocyte Count
|Rights: ||Archived with thanks to Journal of Acquired Immune Deficiency Syndromes (1999)|
|Appears in topics: ||HIV/AIDS|
|Related articles on PubMed|
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
Keiser O, Chi BH, Gsponer T, Boulle A, Orrell C, Phiri S, Maxwell N, Maskew M, Prozesky H, Fox MP, Westfall A, Egger M, IeDEA Southern Africa Collaboration
2011 Sep 10
Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia.
Chi BH, Mwango A, Giganti M, Mulenga LB, Tambatamba-Chapula B, Reid SE, Bolton-Moore C, Chintu N, Mulenga PL, Stringer EM, Sheneberger R, Mwaba P, Stringer JS
2010 May 1
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G, Ladisa N, Zazzi M, Trezzi M, Cicconi P, Corsi P, Nasta P, Cauda R, De Luca A, UCSC cohort, MASTER cohort, ARCA cohort
|See all 173 articles|
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.